Edward Yu
About Edward Yu
Edward Yu is the Associate Director of US Hematology/Oncology at Bristol Myers Squibb, with a strong background in epidemiology and real-world evidence generation.
Company
Edward Yu is currently an Associate Director at Bristol Myers Squibb. Located in New Jersey, United States, the company focuses on the development and distribution of innovative medicines for serious diseases, with particular emphasis on Hematology and Oncology. Edward has been with the company since March 2021, concentrating on real-world evidence generation for these therapeutic areas.
Title
Edward Yu holds the position of Associate Director in the US Hematology/Oncology division at Bristol Myers Squibb since March 2021. His role involves focusing on the generation of real-world evidence to support the treatment of hematologic and oncologic conditions.
Education and Expertise
Edward Yu earned a BA in Biochemistry from Dartmouth College and a Doctor of Science (D.Sc.) in Epidemiology and Nutrition from Harvard T.H. Chan School of Public Health. His educational background provides a solid foundation in epidemiology, causal inference, and study design. These disciplines have equipped him to contribute significantly to the fields of hematology and oncology through his work at Bristol Myers Squibb and previous roles.
Professional Background
Edward Yu has extensive experience in data analysis and real-world evidence generation. Before joining Bristol Myers Squibb, he worked at Flatiron Health as a Quantitative Scientist, where he led a team for a brief period in 2021 and held a position from 2019 to 2021. His role at Flatiron Health involved developing quantitative methods for healthcare data analysis. Prior to that, he was a Senior Scientist at Aetion from 2018 to 2019 and a Research Assistant at Joslin Diabetes Center from 2011 to 2013.
Achievements and Contributions
Edward Yu has authored multiple peer-reviewed publications in the fields of epidemiology and real-world evidence. His work in advancing causal inference and study design methodologies has had a notable impact on epidemiology. During his tenure at Flatiron Health, he contributed significantly to the development of quantitative methods for healthcare data analysis. At Bristol Myers Squibb, he has continued to drive the generation of real-world evidence in hematology and oncology, contributing to the advancement of treatments and therapies in these critical areas.